TW200900417A - Method for stereoselective preparation and separation of tri-o-acetyl-5-deoxy-β]-D-ribofuranose - Google Patents
Method for stereoselective preparation and separation of tri-o-acetyl-5-deoxy-β]-D-ribofuranose Download PDFInfo
- Publication number
- TW200900417A TW200900417A TW097106815A TW97106815A TW200900417A TW 200900417 A TW200900417 A TW 200900417A TW 097106815 A TW097106815 A TW 097106815A TW 97106815 A TW97106815 A TW 97106815A TW 200900417 A TW200900417 A TW 200900417A
- Authority
- TW
- Taiwan
- Prior art keywords
- formula
- compound
- solvent
- deoxy
- group
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 238000000926 separation method Methods 0.000 title claims description 6
- 230000000707 stereoselective effect Effects 0.000 title abstract description 4
- 238000002360 preparation method Methods 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 25
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- -1 cyclic amine Chemical class 0.000 claims description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000001953 recrystallisation Methods 0.000 claims description 11
- 150000003973 alkyl amines Chemical class 0.000 claims description 10
- 239000012296 anti-solvent Substances 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 claims description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims 3
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims 2
- IXADHCVQNVXURI-UHFFFAOYSA-N 1,1-dichlorodecane Chemical compound CCCCCCCCCC(Cl)Cl IXADHCVQNVXURI-UHFFFAOYSA-N 0.000 claims 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 abstract description 4
- 230000021736 acetylation Effects 0.000 abstract description 2
- POQVFSLEXBFRFI-UHFFFAOYSA-N C[CH-]C(C)=O Chemical compound C[CH-]C(C)=O POQVFSLEXBFRFI-UHFFFAOYSA-N 0.000 abstract 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 abstract 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 abstract 1
- NXEJETQVUQAKTO-PRTGYXNQSA-N [(2r,3r,4r,5s)-4,5-diacetyloxy-2-methyloxolan-3-yl] acetate Chemical compound C[C@H]1O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O NXEJETQVUQAKTO-PRTGYXNQSA-N 0.000 abstract 1
- 229960004117 capecitabine Drugs 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 7
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000009987 spinning Methods 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical group NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- APQIUTYORBAGEZ-UHFFFAOYSA-N 1,1-dibromoethane Chemical compound CC(Br)Br APQIUTYORBAGEZ-UHFFFAOYSA-N 0.000 description 1
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- NXEJETQVUQAKTO-ZBCCYFLUSA-N [(2r,3r,4r)-4,5-diacetyloxy-2-methyloxolan-3-yl] acetate Chemical compound C[C@H]1OC(OC(C)=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O NXEJETQVUQAKTO-ZBCCYFLUSA-N 0.000 description 1
- ZJCFNHIEEPXKSO-UHFFFAOYSA-N ac1l9lei Chemical compound C.C.C ZJCFNHIEEPXKSO-UHFFFAOYSA-N 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- 229910052956 cinnabar Inorganic materials 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000007730 finishing process Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000006146 oximation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010956 selective crystallization Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B31/00—Preparation of derivatives of starch
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
200900417 九、發明說明: L 明所屬領】 發明領域 ~0'乙酸-5-去氧- 瘤達的中間物。 本發明關於一種立體選擇性製備與分離三 5 /3 -D-呋喃核糖的方法,該呋喃核糖用作製備戴 發明背景 截瘤達,(一具有呋喃核糖主鏈的核苦), J,為—抗腫瘤 劑,經口服投予該劑以治療轉移性乳癌與直腸痒並具有 10其中連接在吱喃核糖的位置1上的5-氟胞嘧D定部分具有 位向的下列所示之立體化學結構:200900417 IX, invention description: L Ming belongs to the field of invention] ~0 'acetate-5-deoxy-tumor intermediate. The invention relates to a method for stereoselectively preparing and isolating tris/5-D-ribofuranose, which is used for preparing the background of the invention, (a nuclear bitter with a ribofuranose backbone), J, An antitumor agent, which is administered orally to treat metastatic breast cancer and rectal itching and has a 10-fluorocytosine moiety in which the 5-fluorocytosine moiety attached to position 1 of the glucopyranose has a orientation as shown below. Chemical structure:
如美國專利第5,453,497號中所述,截瘤達可藉由將三 -0-乙醯-5-去氧j-D-吱喃核糖以氟胞嘧啶糖化及接著使 15所得產物接受胺甲醯基化反應與水解而製備,如反應流程 (A)中所示。 反應流裎ίΑ、As described in U.S. Patent No. 5,453,497, the nodulation can be achieved by saccharification of trioxo-5-deoxyjD-pyridose ribose with fluorocytosine followed by accepting the amine for mercaptolation of the product obtained by 15 The reaction is prepared by hydrolysis and is shown in the reaction scheme (A). Reaction flow 裎 Α,
(V) 5 (I) 200900417 上述所使用的原料,式⑴之三_〇_乙酿-5-去氧_召七_„夫 。南核糖係根據在美國專利第4,340,729號中所述之方法製 備,如反應流程⑼中所示。特別地,⑴將式(1¥)化合物水 解’以獲得式(III)之三元醇化合物;(ii)在吼咬中使用乙酸 5酐將式(ΠΙ)之三元醇化合物乙醯化,以獲得式(II)之三_〇_ 乙醯-5·•去氧呋喃核糖,其為關於在位置1上的乙醯基之 /5 _/α-變旋異構物混合物;(iii)使反應混合物接受真空蒸 顧’以純化/3-/α-變旋異構物混合物;及(iv)將式(I)之卢_ 變旋異構物自該混合物分離。 10 反應流程(B)(V) 5 (I) 200900417 The above-mentioned raw materials, the formula (1) _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Preparation, as shown in the reaction scheme (9). Specifically, (1) hydrolyzing a compound of the formula (1) to obtain a triol compound of the formula (III); (ii) using acetic anhydride 5 in a bite (将) The triol compound is acetylated to obtain the ternary oxime of the formula (II) _ 〇 醯 · · 去 去 去 , , , , 关于 关于 关于 关于 关于 在 在 在 在 在a mixture of spinning isomers; (iii) subjecting the reaction mixture to vacuum distillation to purify the /3-/α-raceomer mixture; and (iv) the _ _ _ _ Separation from the mixture. 10 Reaction Scheme (B)
再者,在吡啶中三元醇化合物以乙酸酐來獲得三_〇_乙 醯-5-去氧-D-呋喃核糖的乙醯化反應也被敘述於其他的報 導中[J. Med· Chem·,2000,vol. 43,pp 2566-2574]、 15 [Carbohydrate Research, 2003,vol. 338, pp 303-306]、 [Nuclear Medicine and Biology, 2004, vol. 31,pp 1033-1041] 及[J· Am. Chem· Soc.,1957, vol. 79, pp 5534-5540]。 然而,上述製備三-O-乙醯-5-去氧-D-呋喃核糖的方法 由於使用吡啶作為溶劑而受到各種問題的牵制:在反應之 20 後的整理量非常大且需要複雜的多步驟整理程序;變旋 異構物形成的選擇性低,三-0-乙醯-5-去氧-D-呋喃核糖產 物的/5-/α -變旋異構物之比不超過3 : 1至3.5 : 1 ;及由於 200900417 有相對大量的α -變旋異構物存在,藉由再結晶作用將所欲 之式(I)之召-變旋異構物自/3-/α-變旋異構物混合物分離 有困難,而且只得到約35至40%之產率。 因此,本發明企圖發展一種製備三-〇-乙醯-5-去氧-/5 5 -D-呋喃核糖的改進方法,並發現/3-/α-變旋異構物之比可 藉由在乙醯化反應期間使用烷胺或環胺鹼類取代吡啶而顯 著地改進。 【發明内容】 發明概要 10 據此,本發明的一目的係提供一種製備具有高的/5-變 旋異構物比之二_〇_乙酿-5-去氧-A -D-n夫喃核糖的方法。本 發明的另一目的係提供一種將三-0-乙醯-5-去氧-D-呋喃核 糖的純yS-變旋異構物自其之/5-/α-變旋異構物混合物分 離的簡單且容易的方法。 15 根據本發明的一個觀點,其係提供一種製備式⑴之三 -0-乙酿-5-去氧-卢-D-a夫喃核糖的方法,其包含步驟. ⑴在烷胺或環胺的存在下於有機溶劑中進行式(III)化 合物與乙酸酐的反應,以獲得式(II)化合物;及 (ii)藉由使用溶劑及反溶劑的再結晶作用分離式⑴化 20 合物與式(II)化合物: 200900417Furthermore, the acetylation reaction of tris-ol compounds in pyridine with acetic anhydride to obtain tris-oxime-5-deoxy-D-ribofuranose has also been described in other reports [J. Med·Chem ·, 2000, vol. 43, pp 2566-2574], 15 [Carbohydrate Research, 2003, vol. 338, pp 303-306], [Nuclear Medicine and Biology, 2004, vol. 31, pp 1033-1041] and [ J. Am. Chem. Soc., 1957, vol. 79, pp 5534-5540]. However, the above process for preparing tris-O-acetam-5-deoxy-D-ribofuranose is hampered by various problems due to the use of pyridine as a solvent: the amount of finishing after the reaction 20 is very large and requires complicated multi-steps. Finishing procedure; the selectivity of the formation of the racemic isomer is low, the ratio of the /5-/α-raceomer of the trioxo-5-deoxy-D-ribofuranose product does not exceed 3:1 To 3.5:1; and due to the relatively large amount of α-raceomers present in 200900417, the desired formulae of the formula (I) is changed from /3-/α- by recrystallization. Separation of the mixture of isomers is difficult and only yields from about 35 to 40% are obtained. Accordingly, the present invention seeks to develop an improved process for the preparation of tris-indole-5-deoxy-5/5-D-ribofuranose and finds that the ratio of /3-/[alpha]-helical isomers can be Significant improvement is achieved by the use of alkylamines or cyclic amine bases in place of pyridine during the oximation reaction. SUMMARY OF THE INVENTION According to the present invention, it is an object of the present invention to provide a bismuth-5-deoxy-A-Dn ribose ribose having a high ratio of /5-rotational isomers. Methods. Another object of the present invention is to provide a pure yS-raceomer of trioxo-5-deoxy-D-ribofuranose from its/5-/α-spinning isomer mixture A simple and easy way to separate. According to one aspect of the present invention, there is provided a process for the preparation of the trioxo-5-deoxy-lu-Da-flana ribose of the formula (1), which comprises the steps. (1) in the presence of an alkylamine or a cyclic amine The reaction of the compound of the formula (III) with acetic anhydride in an organic solvent to obtain the compound of the formula (II); and (ii) the separation of the compound (1) and the formula by recrystallization using a solvent and an antisolvent ( II) Compound: 200900417
L實施方式3 較佳實施例之詳細說明 根據本發明用於立體選擇性乙醯化反應及分離/5 -變 5 旋異構物的方法係顯示於流程(C)中。 流程(C)L. Embodiment 3 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS A method for stereoselective acetamylation reaction and separation of /5-dependent spiromers according to the present invention is shown in Scheme (C). Process (C)
(IV) (ill) (II) (I) 特別地,式(IV)之甲基縮丙酮化物(methylacetonide)化 合物係藉由美國專利第4,340,729號中所述之慣例方法去保 10 護,以獲得式(III)之三元醇化合物,其具有約1 : 1至2 : 1 的α -對/5 -之比的α -//3 -變旋異構物混合物型式。變旋異構 物可視需要藉由於下一步驟中使用的管柱層析法分離。式 (IV)之曱基縮丙酮化物化合物可藉由美國專利第4,340,729 號中所述之方法輕易地製備。 15 在乙醯化式(III)之三元醇化合物的步驟中,可使用以 式(III)化合物為基準計3莫耳當量或更多的量之烷胺或環胺 200900417 代替如先前技藝所教示的使用純α比咬作為溶劑,以達成三 元醇化合物與乙酸奸的南立體選擇性反應.產物式(II)之 三-0-乙醯-5-去氧呋喃核糖包括一顯著的高万-變旋異 構物含量,α-對/5-變旋異構物之比為1 : 10或更高。該富 5含々_變旋異構物之產物可接受使用溶劑或反溶劑的再結 晶作用,以獲得具有99.5%及更高的高產率之南純度的式(I) 之/3 -變旋異構物。 如上所述,不像使用過量純吡啶作為溶劑的慣例方 法,本發明的方法得到具有高的冷-變旋異構物含量之三 10乙醯-5-去氧-D_呋喃核糖,該方法係使用等量的烷胺或環胺 與有機溶劑一起進行。因此’在反應之後的整理過程大為 簡化。亦即,純三-0-乙醯-5-去氧-石-D-咬喃核糖可從乙醯 化反應混合物回收,並可以使用溶劑及反溶劑的簡單式再 詰晶作用輕易地獲得80%及更高的高產率,而不進行在慣 15 例方法中所使用的高真空蒸餾作用。 在根據本發明的乙酿化反應中所使用的有機溶劑可選 自由四氫呋喃、乙腈、二氣甲烷 '氣仿、二溴乙烷 '二氯 乙炫、乙酸乙酿、甲苯及其混合物所組成的群組中,以二 氯甲炫較佳。 20 在本發明所使用的烷胺或環胺可選自由三乙胺、正_三 丁胺、二環己胺、四甲基乙二胺、二異丙基乙胺、N_甲基 鳴淋及其混合物所組成的群組,以三乙胺較佳。 根據所使用的烷胺或環胺種類,超越α-變旋異構物的 變旋異構物之選擇性從至少1〇 :丨增加至15 :丨,其中三 200900417 乙胺的使用較佳,而°辰σ定無效。 在本發明中,以式(III)化合物為基準計,烷胺或環胺 的量可為3至12莫耳當量,以4至5莫耳當量較佳。 根據本發明的乙醯化反應可在10至50°C下,以5至25 5 °C較佳,進行6至24小時。 在乙酿化反應之後,由於其高的点-變旋異構物含量而 以一固體獲得式(II)之三-0-乙醯-5-去氧-D-呋喃核糖,不像 使用吡啶的慣例方法所獲得的產物為油或半固體。 以本發明的乙醯化方法所獲得的式(II)之三-0-乙醯-5-10 去氧-D-呋喃核糖主要由所欲之yS-變旋異構物所組成,α-變旋異構物含量僅6至9%。為了從其獲得純的/5-變旋異構 物,α-變旋異構物可藉由依照任何慣例方法的再結晶作用 而移除。例如,純的/5 -變旋異構物可藉由將反溶劑加入由 將該變旋異構物混合物溶解在一適當的溶劑中所獲得的溶 15 液中,過濾以移除含有變旋異構物的過濾物,及收集成 為固體的/5-變旋異構物而輕易地分離。 在再結晶作用中所使用的適當溶劑可為一極性有機溶 劑,其係選自由甲醇、乙醇、丙醇、異丙醇、正丁醇、丙 酮、乙腈、四氫呋喃、氯仿、二氯曱烷、乙酸乙酯、二乙 20 醚及其混合物所組成的群組,以異丙醇較佳。在再結晶作 用中所使用的反溶劑可為一非極性有機溶劑,其係選自由 正己烧、庚烧、辛烧、壬烧、石油醚、異丙醚及其混合物 所組成的群組,或可為水,以正己烷或水較佳。 再結晶作用可在-60至30°C下進行,以-10至5°C較佳, 10 200900417 並且溶劑及反溶劑量,以式(II)之三_〇_乙酿_5_去氧七 核糖為基準計,可分別為2至5倍(體積/重量)及5至^ 積/重量)。 σ(體 在再結晶作用之後所獲得的/5-變旋異構物具有—至 5少99.5%之純度,α_變旋異構物含量少於〇5%。 如上所述,以立體選擇性製備式⑴之三乙酿_5_去氧 -/3-D·咬喃核糖的本發明方法,與慣例的方法相比,顯干出 顯著改進的立體選擇性,且與以慣例的方法所獲得的小於 35至40%之產率減,得到至少75%的高產率。 、 1〇下列的實例意欲進—步說明本發明,而非限制其範圍。 在下列的實例中,在式⑴化合物的情況中,GC(氣相 層析法)係使用氰丙基笨基聚石夕氧烧管柱(内徑:〇 32毫米, 長度60公尺’厚度:丨8微米)(例如,db 624)操作,並且試 驗溶液係藉由將⑽毫克式⑴化合物溶解在二甲基亞石風 15中,以製成25毫升溶液而製備。 趣:式(II)之三-〇乙聽_5·去氧如夫仙糖的立鍾選擇 性製備作用(IV) (ill) (II) (I) In particular, the methylacetonide compound of the formula (IV) is protected by the conventional method described in U.S. Patent No. 4,340,729. A triol compound of formula (III) having a ratio of a-//3-isomer mixture of about 1:1 to 2:1 ratio of α-pair/5-. The racemic isomers can be separated by column chromatography as used in the next step, as desired. The fluorenyl acetonide compound of the formula (IV) can be easily prepared by the method described in U.S. Patent No. 4,340,729. In the step of acetylating the triol compound of the formula (III), an alkylamine or a cyclic amine 200900417 in an amount of 3 mole equivalents or more based on the compound of the formula (III) may be used instead of the prior art. The teaching uses a pure alpha ratio bite as a solvent to achieve a south stereoselective reaction of a triol compound with acetic acid. The product of formula (II) tris-0-acetam-5-deoxyribofuranose includes a significant high The ratio of the osmolality to the α-p-/5-stacked isomer is 1:10 or higher. The product of the cerium-rich vortexomer can be subjected to recrystallization using a solvent or an anti-solvent to obtain a /3 - vortex of the formula (I) having a high purity of 99.5% and higher in south purity. Isomer. As described above, unlike the conventional method using an excess of pure pyridine as a solvent, the method of the present invention obtains tris10-acetam-5-deoxy-D-ribofuranose having a high cold-rotational isomer content. The use of an equivalent amount of an alkylamine or a cyclic amine is carried out together with an organic solvent. Therefore, the finishing process after the reaction is greatly simplified. That is, pure tris-O-acetam-5-deoxy-stone-D-arabose can be recovered from the acetamidine reaction mixture, and can be easily obtained by simple recrystallization of solvent and antisolvent. High yields of % and higher without the high vacuum distillation used in the conventional 15 methods. The organic solvent used in the brewing reaction according to the present invention may be selected from the group consisting of tetrahydrofuran, acetonitrile, di-methane methane, dibromoethane, dichloroethane, acetic acid, toluene and mixtures thereof. Among the groups, it is preferred to use dichloromethane. 20 The alkylamine or cyclic amine used in the present invention may be selected from triethylamine, n-tributylamine, dicyclohexylamine, tetramethylethylenediamine, diisopropylethylamine, N-methylamine A group consisting of a mixture thereof and triethylamine is preferred. Depending on the alkylamine or cyclic amine species used, the selectivity of the racemic isomer beyond the α-helical isomer increases from at least 1 〇:丨 to 15:丨, of which three 200900417 ethylamine is preferred for use. And ° σ σ is invalid. In the present invention, the amount of the alkylamine or cyclic amine may be from 3 to 12 mol equivalents, preferably from 4 to 5 mol equivalents, based on the compound of the formula (III). The acetylation reaction according to the present invention can be carried out at 10 to 50 ° C, preferably 5 to 25 5 ° C, for 6 to 24 hours. After the B-stuffing reaction, the tri-O-acetyl-5-deoxy-D-ribofuranose of the formula (II) is obtained as a solid due to its high point-rotational isomer content, unlike the use of pyridine. The product obtained by the conventional method is oil or semi-solid. The trioxo-5-10-deoxy-D-ribofuranose of the formula (II) obtained by the acetylation method of the present invention is mainly composed of the desired yS-raceomer, α- The content of the spinning isomer is only 6 to 9%. In order to obtain a pure/5-rotational isomer therefrom, the α-rotation isomer can be removed by recrystallization according to any conventional method. For example, a pure /5-rotational isomer can be removed by adding an anti-solvent to a solution 15 obtained by dissolving the mixture of the rotatory isomers in a suitable solvent. The filtrate of the isomer is easily separated by collecting as a solid/5-. A suitable solvent for use in the recrystallization may be a polar organic solvent selected from the group consisting of methanol, ethanol, propanol, isopropanol, n-butanol, acetone, acetonitrile, tetrahydrofuran, chloroform, dichloromethane, acetic acid. The group consisting of ethyl ester, diethyl 20 ether and mixtures thereof is preferably isopropanol. The anti-solvent used in the recrystallization may be a non-polar organic solvent selected from the group consisting of n-hexanol, heptane, cinnabar, teriyaki, petroleum ether, isopropyl ether, and mixtures thereof, or It may be water, preferably n-hexane or water. Recrystallization can be carried out at -60 to 30 ° C, preferably -10 to 5 ° C, 10 200900417 and the amount of solvent and anti-solvent, with the formula (II) _ _ _ _ _ 5 _ deoxygenation Based on the seven-ribose sugar, it can be 2 to 5 times (volume/weight) and 5 to 2 product/weight, respectively. σ (the body of the 5 - mutated isomer obtained after recrystallization has - to less than 99.5% purity, the α_ Cyclone isomer content is less than 〇 5%. As described above, with stereoselection The method of the present invention for preparing the triethyl _5_deoxy-/3-D· tranose ribose of the formula (1) exhibits significantly improved stereoselectivity compared to the conventional method, and in a conventional manner The obtained yield reduction of less than 35 to 40% yields a high yield of at least 75%. The following examples are intended to illustrate the invention without limiting its scope. In the following examples, in the formula (1) In the case of the compound, GC (gas chromatography) is a column of cyanopropyl stupid polyoxygen tube (inner diameter: 〇32 mm, length 60 m' thickness: 丨8 μm) (for example, db 624) Operation, and the test solution was prepared by dissolving (10) mg of the compound of the formula (1) in dimethyl sulphur wind 15 to prepare a 25 ml solution. Interest: Formula (II) 3 - 〇 B listen _ 5 ·Selective preparation of degassing such as vanillin
V^〇h ——.Vr〇At HO 〇H ? \V^〇h ——.Vr〇At HO 〇H ?
AeO OAc 0") (II) (l l)M使用二乙胺作為驗的程序 20 將100公克的甲基-2,3-〇-異亞丙-5-去氧ID-咬鳴核 糖加入500亳升〇·〇2Μ硫酸中,並在8〇至85<^下攪拌2小時。 使溫度下降至45至耽,並在減財移除水,直到總體積 11 200900417 由2/3減少至1/2為止。將500毫升0 02M硫酸加入所得溶液 中,並在80至85。(:下攪拌1小時。使溫度下降至室溫,將所 得溶液以0·2Μ碳酸鈉中和至pH 5.3至5.5,並在減壓下濃 縮。將所得殘餘物懸浮在1,000毫升乙腈中,並將5〇公克無 水硫酸鈉加入其中及攪拌1小時。將所得混合物經由矽藻土 官柱過濾,接著將其以100毫升乙腈清洗,將過濾物及清洗 物合併,並在減壓下濃縮,以移除溶劑。將1,〇〇〇毫升二氯 甲烷及370毫升三乙胺加入所得殘餘物中,同時使溫度維持 在5。(:下,加入235_5毫升乙酸酐及攪拌20小時。在反應完 成之後,將1,000毫升水加入所得反應混合物中,檀拌及將 有機層分離。接著將有機層以1,000毫升數份的丨N HC1、飽 和碳酸氫鈉及食鹽水連續清洗,並接著經無水硫酸鈉乾 垛。將所得有機層在減壓下濃縮,以獲得標題化合物(140.8 公克)。將因此獲得的產物以GC分析,其顯示產物包括1 : 15 U.8之比的α-與石-變旋異構物。 4 NMR (300MHz,CDC13):(泠-變旋異構物)δ 6-〇9(s,1H), 5.30 5.32(dd,lH), 5.06 5.10(dd,lH), 4.26(q,lH), 2-l〇(s,3H),2.07(s,3H),2.05(s,3H),1.35(d,3H)。 4 NMR (300MHz,CDC13) : ( a -變旋異構物)<5 2〇 6-2l(d,lH), 5.11(dd,lH), 4.8(dd,lH), 4.15 4.20(m,lH), 1970,111),1.92(8,311),1.89(8,311),1.21((1,311)° d-2)當使用三-正丁胺作為鹼的程序 重複(1-1)之最初程序,除了使用5公克甲基-2,3-0-異亞 丙-5-去氧-/5-D-呋喃核糖之外,以獲得三元醇化合物。接 12 200900417 著,將50毫升二氯甲烷及31·6毫升三-正丁胺加入所得殘餘 物中,將11.8毫升乙酸酐緩慢加入其中,並在室溫下攪拌12 小時。在反應完成之後,將50毫升水加入反應混合物中, 攪拌及將有機層分離。接著將有機層以50毫升數份的1N 5 HC1、飽和碳酸氫鈉及食鹽水連續清洗,經無水硫酸納乾燥 及過濾。將所得過濾物在減壓下濃縮,以獲得標題化合物 (7公克)。將因此獲得的產物以GC分析,其顯示產物包括j : 11.2之比的α -與/5 -變旋異構物。 (1-3)當使用四甲基乙二胺作為鹼的程序 10 重複(1-1)之最初程序,除了使用5公克曱基-2,3-〇_異亞 丙-5-去氧-/S-D-呋喃核糖之外,以獲得三元醇化合物。接 著,將50毫升二氯甲烷及20毫升四甲基乙二胺加入所得殘 餘物中,將11.8毫升乙酸酐緩慢加入其中,並在室溫下攪掉 12小時。在反應完成之後,將50毫升水加入反應混合物中, 15攪拌及將有機層分離。接著將有機層以50毫升數份的1N HC1、飽和碳酸氫鈉及食鹽水連續清洗,經無水硫酸鈉乾燥 及過濾。將所得過濾物在減壓下濃縮,以獲得標題化合物 (7公克)。將因此獲得的產物以Gc分析,其顯示產物包括^ : 10.3之比的α-與点-變旋異構物。 20生毯逢^ :當使用吡啶作為有機驗的程序 將5公克甲基-2,3-0-異亞丙_5_去氧_石_D_吱喃核糖加 入25毫升〇.〇2M硫酸中,並在肋至“它下攪拌2小時。使溫 度下降至45至5〇t,並在減壓下移除水,直到總體積由奶 減少至1/2為止。將25毫升〇.〇2M硫酸加入所得溶液中,並 13 200900417 •在80至85°C下攪拌1小時。使溫度下降至室溫,將所得溶液 • 以0.2M碳酸鈉中和至pH 5.3至5.5,並在減壓下濃縮。將所 得殘餘物懸浮在50毫升乙腈中,並將5公克無水硫酸鈉加人 其中及攪拌1小時。將所得混合物經由矽藻土管柱過濾,接 . 5 著將其以5毫升乙腈清洗,將過濾物及清洗物合併,並在減 壓下濃縮。將11.8毫升乙酸酐及25毫升吡啶加入所得殘餘物 中,並攪拌12小時。在反應完成之後’將1〇〇毫升水加入其 中’擾摔1小時’並將所得溶液以1 〇〇毫升二氯甲烧萃取。 將有機層以100毫升數份的IN HC1清洗三次,然後以100毫 10升數份的飽和碳酸氫鈉及食鹽水連續清洗。將有機層經無 水硫酸鈉乾燥及過濾。將所得過濾物在減壓下濃縮,以獲 得標題化合物(6.8公克)。將因此獲得的油狀產物wGc分AeO OAc 0") (II) (ll) M using diethylamine as a procedure for the test 20 Add 100 grams of methyl-2,3-indole-5-deoxy ID-bisting ribose to 500 亳Rise in Μ2Μ sulfuric acid and stir for 2 hours at 8〇 to 85<^. Decrease the temperature to 45 to 耽 and remove the water in the loss of money until the total volume 11 200900417 is reduced from 2/3 to 1/2. 500 ml of 0 02 M sulfuric acid was added to the resulting solution at 80 to 85. (The mixture was stirred for 1 hour. The temperature was lowered to room temperature, the resulting solution was neutralized to pH 5.3 to 5.5 with 0. 2 Μ sodium carbonate, and concentrated under reduced pressure. The obtained residue was suspended in 1,000 ml of acetonitrile. 5 gram of anhydrous sodium sulfate was added thereto and stirred for 1 hour. The resulting mixture was filtered through a column of celite, and then washed with 100 ml of acetonitrile, and the filtrate and washings were combined and concentrated under reduced pressure. To remove the solvent, 1. 〇〇〇ml of dichloromethane and 370 ml of triethylamine were added to the residue while maintaining the temperature at 5. (:, 235_5 ml of acetic anhydride was added and stirred for 20 hours. After the reaction was completed, 1,000 ml of water was added to the obtained reaction mixture, and the organic layer was separated, and then the organic layer was successively washed with 1,000 ml portions of 丨N HCl, saturated sodium hydrogencarbonate and brine, and then Drying over anhydrous sodium sulfate. The obtained organic layer was concentrated under reduced pressure to give the title compound (140.8 g). The product thus obtained was analyzed by GC, which showed that the product included a ratio of 1:15 U.8. With stone-variation Isomers. 4 NMR (300MHz, CDC13): (泠-Zero isomers) δ 6-〇9(s,1H), 5.30 5.32(dd,lH), 5.06 5.10(dd,lH), 4.26( q,lH), 2-l〇(s,3H),2.07(s,3H),2.05(s,3H),1.35(d,3H). 4 NMR (300MHz, CDC13) : ( a - Structure) <5 2〇6-2l(d,lH), 5.11(dd,lH), 4.8(dd,lH), 4.15 4.20(m,lH), 1970,111),1.92(8,311), 1.89 (8, 311), 1.21 ((1, 311) ° d-2) The initial procedure for repeating (1-1) when using tri-n-butylamine as the base, except for the use of 5 gram methyl-2,3-0- In addition to propion-5-deoxy-/5-D-ribofuranose, a triol compound is obtained. In 12200900417, 50 ml of dichloromethane and 31.6 ml of tri-n-butylamine are added to the residue. 11.8 ml of acetic anhydride was slowly added thereto, and stirred at room temperature for 12 hours. After the reaction was completed, 50 ml of water was added to the reaction mixture, stirred and the organic layer was separated. Then the organic layer was added in 50 ml portions. 1N 5 HCl, saturated sodium hydrogencarbonate and brine were washed successively, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to give the title compound. The product thus obtained was analyzed by GC, which showed that the product included α- and /5-raceomers of a ratio of j: 11.2. (1-3) When tetramethylethylenediamine was used as a base Procedure 10 The initial procedure of (1-1) was repeated except that 5 g of fluorenyl-2,3-indole-5-deoxy-/SD-ribofuranose was used to obtain a triol compound. Next, 50 ml of dichloromethane and 20 ml of tetramethylethylenediamine were added to the residue, and 11.8 ml of acetic anhydride was slowly added thereto, and stirred at room temperature for 12 hours. After the reaction was completed, 50 ml of water was added to the reaction mixture, 15 was stirred and the organic layer was separated. The organic layer was successively washed with 50 ml portions of 1N HCl, saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate and filtered. The obtained filtrate was concentrated under reduced pressure to give the title compound (7 g). The product thus obtained was analyzed by Gc, which showed that the product included the α-and-dot-spin isomer of the ratio: 10.3. 20 raw carpets ^: When using pyridine as an organic test procedure, add 5 grams of methyl-2,3-0-isopropylene _5_deoxy_stone_D_pyranose to 25 ml of 〇.〇2M sulfuric acid Medium, and in the ribs to "It is stirred for 2 hours. Let the temperature drop to 45 to 5 〇t, and remove the water under reduced pressure until the total volume is reduced from milk to 1/2. 25 ml 〇.〇 2M sulfuric acid was added to the resulting solution, and 13 200900417 • Stir at 80 to 85 ° C for 1 hour. The temperature was lowered to room temperature, and the resulting solution was neutralized with 0.2 M sodium carbonate to pH 5.3 to 5.5, and decompressed. The residue was suspended in 50 ml of acetonitrile, and 5 g of anhydrous sodium sulfate was added thereto and stirred for 1 hour. The resulting mixture was filtered through a celite column, and then washed with 5 ml of acetonitrile. The filtrate and the washings were combined and concentrated under reduced pressure. 11.8 ml of acetic anhydride and 25 ml of pyridine were added to the residue and stirred for 12 hours. After the reaction was completed, '1 ml of water was added thereto' Spoiled for 1 hour' and extracted the resulting solution with 1 〇〇 ml of methylene chloride. The organic layer was 100 mM. Several portions of IN HC1 were washed three times, and then washed successively with 100 ml of a portion of saturated sodium hydrogencarbonate and brine. The organic layer was dried over anhydrous sodium sulfate and filtered. The title compound (6.8 g). The oily product wGc thus obtained
趣I變旋異構物(式(1)之三_〇_己殖_5_去氧j_D咬鳴 15 核糖)的選擇性結晶作用Selective crystallization of the I-spinning isomer (formula (1) _ _ _ _ _ _ 5 _ deoxy j_D gnash 15 ribose)
份接受如下述之再結晶作用。 20 (2-1) 醇中, 將28公克α/石-變旋異構物混合物溶解在獅升異丙 醇中,亚將168毫升己烧逐滴加入其中。將所得溶液在 14 200900417 。(:下經3小時熟化,並過濾,以獲得成為白色固體的標題化 合物(21.9公克,總產率:79·5%)。The fractions were subjected to recrystallization as described below. 20 (2-1) In the alcohol, 28 g of the α/rock-raceomer mixture was dissolved in lion isopropyl alcohol, and 168 ml of hexane was added dropwise thereto. The resulting solution was at 14 200900417. (: The title compound was obtained (31.9 g, total yield: 79.5%).
熔點:65-66°C /3 變旋異構物含量:99.6%( α -變旋異構物含量:0.1 %) 5 4 NMR (300MHz,CDC13) : ( /3 -變旋異構物)5 6.09(s,lH), 5.30 5.32(dd,lH), 5.06 5.10(dd,lH), 4.26(q,lH), 2.10(s,3H), 2.07(s,3H), 2.05(s,3H), 1.35(d,3H)。 (2-2) 將28公克α/冷-變旋異構物混合物溶解在56毫升異丙 10 醇中,並將168毫升己烷逐滴加入其中。將所得溶液在0至5 °C下經3小時熟化,並過濾,以獲得成為白色固體的標題化 合物(21.0公克,總產率:76_4%)。 /3-變旋異構物含量:99.7%(α-變旋異構物含量:0.05%) 熔點及1H-NMR數據與以實例2-1中所獲得的該等相同。 15 (2-3) 將28公克α//3 -變旋異構物混合物溶解在56毫升異丙 醇中,並將168毫升蒸餾水逐滴加入其中。將所得溶液在5 °C下經7小時熟化,並過濾,以獲得成為白色固體的標題化 合物(21.3公克,總產率:77.4%)。 20 石-變旋異構物含量:99.5%( α -變旋異構物含量:0.1 %) 熔點及1H-NMR數據與以實例2-1中所獲得的該等相同。 (2-4) 將28公克〇:/召-變旋異構物混合物溶解在56毫升異丙 醇中,並將112毫升蒸餾水逐滴加入其中。將所得溶液在5 15 200900417 °C下經7小時熟化,並過濾,以獲得成為白色固體的標題化 合物(20.7公克,總產率:75.4%)。 /5-變旋異構物含量:99.6%(α-變旋異構物含量:0.1%) 熔點及1Η - N M R數據與以實例2 -1中所獲得的該等相同。 5 (2-5) 將28公克α//3 -變旋異構物混合物溶解在56毫升二氯 甲烷中,並將168毫升己烷逐滴加入其中。將所得溶液在10 °C下經3小時熟化,並過濾,以獲得成為白色固體的標題化 合物(21.1公克,總產率:76.5%)。 10 召-變旋異構物含量:99.5%(α-變旋異構物含量:0.1%) 熔點及1H-NMR數據與以實例2-1中所獲得的該等相同。 比較性實例2 將藉由使用吡啶作為有機鹼所獲得的比較性實例1的6.8 公克變旋異構物混合物(變旋異構物:/5-變旋異構物=1 : 15 3.4)溶解在13.6毫升異丙醇中,並將40.8毫升己烷逐滴加入其 中。將所得溶液在0至5°C下經3小時熟化,並過濾,以獲得 成為乳白色固體的標題化合物(2.5公克,總產率:36.2%)。Melting point: 65-66 ° C /3 Spinal isomer content: 99.6% (α-rotational isomer content: 0.1%) 5 4 NMR (300MHz, CDC13) : ( /3 - torsion isomer) 5 6.09(s,lH), 5.30 5.32(dd,lH), 5.06 5.10(dd,lH), 4.26(q,lH), 2.10(s,3H), 2.07(s,3H), 2.05(s,3H ), 1.35 (d, 3H). (2-2) A 28 g α/cold-rotation isomer mixture was dissolved in 56 ml of isopropyl alcohol, and 168 ml of hexane was added dropwise thereto. The resulting solution was aged at 0 to 5 °C for 3 hours, and filtered to give the title compound (21.0 g,yield: 76_4%) as white solid. /3-Zero isomer content: 99.7% (α-rotational isomer content: 0.05%) The melting point and 1H-NMR data were the same as those obtained in Example 2-1. 15 (2-3) A mixture of 28 g of the α//3-isomer mixture was dissolved in 56 ml of isopropyl alcohol, and 168 ml of distilled water was added dropwise thereto. The resulting solution was aged at 5 °C for 7 hours, and filtered to give the title compound (21.3 g,j. 20 Stone-rotational isomer content: 99.5% (α-rotational isomer content: 0.1%) The melting point and 1H-NMR data were the same as those obtained in Example 2-1. (2-4) A 28 g 〇:/call-raceomer mixture was dissolved in 56 ml of isopropyl alcohol, and 112 ml of distilled water was added dropwise thereto. The resulting solution was aged at 5 15 200900417 °C for 7 hours, and filtered to give the title compound (20.7 g, <RTIgt; /5-Zero isomer content: 99.6% (α-rotational isomer content: 0.1%) Melting point and 1 Η - N M R data are the same as those obtained in Example 2-1. 5 (2-5) 28 g of the α//3-isomer mixture was dissolved in 56 ml of methylene chloride, and 168 ml of hexane was added dropwise thereto. The resulting solution was aged at 10 °C for 3 hours, and filtered to give the title compound (21.1 g,j. 10 Call-spin isomer content: 99.5% (α-rotation isomer content: 0.1%) The melting point and 1H-NMR data were the same as those obtained in Example 2-1. Comparative Example 2 A 6.8 g of a spinning isomer mixture (spin isomer:/5-rotational isomer = 1: 15 3.4) of Comparative Example 1 obtained by using pyridine as an organic base was dissolved. In 13.6 ml of isopropanol, 40.8 ml of hexane was added dropwise thereto. The resulting solution was aged at 0 to 5 °C for 3 hours, and filtered to give the title compound (2.5 g, m.
熔點:63-65°C /3 -變旋異構物含量:99.0%( α -變旋異構物含量:0.6%) 20 【圖式簡單說明】 (無) 【主要元件符號說明】 (無) 16Melting point: 63-65 ° C /3 - Variable isomer content: 99.0% (α - Cyclone content: 0.6%) 20 [Simple description of the diagram] (None) [Key component symbol description] (None ) 16
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020070020336A KR100908363B1 (en) | 2007-02-28 | 2007-02-28 | Stereoselective preparation method of tri-O-acetyl-5-deoxy-β-D-ribofuranose and separation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200900417A true TW200900417A (en) | 2009-01-01 |
Family
ID=39721406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW097106815A TW200900417A (en) | 2007-02-28 | 2008-02-27 | Method for stereoselective preparation and separation of tri-o-acetyl-5-deoxy-β]-D-ribofuranose |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR100908363B1 (en) |
| AR (1) | AR065305A1 (en) |
| TW (1) | TW200900417A (en) |
| WO (1) | WO2008105593A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101013312B1 (en) * | 2007-11-19 | 2011-02-09 | 한미홀딩스 주식회사 | Method for preparing capecitabine and method for preparing β-anomer-enhanced trialkyl carbonate compound |
| EP2210895A1 (en) * | 2009-01-27 | 2010-07-28 | F. Hoffmann-La Roche AG | Process for the recovery of beta-Acetylfuranoside |
| CN102344469A (en) * | 2011-07-26 | 2012-02-08 | 江西科技师范学院 | Catalytic synthesis of 1, 2, 3-O-triacetyl-5-deoxy-D-ribofuranose by solid acid SO42-/γ-AL2O3 |
| CN112125939B (en) * | 2020-07-16 | 2024-10-29 | 中国人民解放军陆军防化学院 | Method for preparing high-purity 5-deoxy-D-ribose |
| CN117229341B (en) * | 2023-11-07 | 2024-02-09 | 成都苑东生物制药股份有限公司 | Capecitabine crystal form I and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1135258A (en) | 1979-06-15 | 1982-11-09 | Richard D'souza | Process for the preparation of 5'deoxy-5-fluorouridine |
| US5252756A (en) | 1992-06-22 | 1993-10-12 | Eli Lilly And Company | Process for preparing beta-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl-arylsulfonates |
| US6831069B2 (en) | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
-
2007
- 2007-02-28 KR KR1020070020336A patent/KR100908363B1/en not_active Expired - Fee Related
-
2008
- 2008-02-12 AR ARP080100589A patent/AR065305A1/en not_active Application Discontinuation
- 2008-02-19 WO PCT/KR2008/000969 patent/WO2008105593A1/en not_active Ceased
- 2008-02-27 TW TW097106815A patent/TW200900417A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080079833A (en) | 2008-09-02 |
| KR100908363B1 (en) | 2009-07-20 |
| WO2008105593A1 (en) | 2008-09-04 |
| AR065305A1 (en) | 2009-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112020507A (en) | Amide compound and method for producing polynucleotide using same | |
| JP2010512365A (en) | Method for producing 4'-azidocytidine derivative | |
| JP2000109497A (en) | Spirocyclic C-glycoside | |
| CN103517911A (en) | Regioselective acylation of rapamycin at the C-42 position | |
| TW200900417A (en) | Method for stereoselective preparation and separation of tri-o-acetyl-5-deoxy-β]-D-ribofuranose | |
| CN104370932A (en) | Process for producing pyripyropene derivative | |
| UA78840C2 (en) | Method for the separation of intermediates useful for the preparation of escitalopram | |
| JP2002530423A (en) | Novel intermediate, method for producing microlide antibiotics using the same | |
| KR20040021670A (en) | Process for the preparation of ribavirin | |
| WO2008087667A1 (en) | Preparative process for artesunate from artemisinin | |
| CN103694291B (en) | Synthesis method for valrubicin | |
| JP2001521037A (en) | Sarcodicin and eleuserobin useful for microtubule stabilization | |
| JP5908479B2 (en) | Novel process for producing 9-deoxo-9a-aza-9a-homoerythromycin A in which C-4 "of cladinose ring is modified with an epoxide group | |
| IL180894A (en) | 1-alpha-halo-2,2-difluoro-2-deoxy-d-ribofuranose derivatives and processes for the preparation thereof | |
| EA019169B1 (en) | A method for the manufacture of highly pure prasugrel | |
| JPH1059994A (en) | Method for producing sialic acid derivative | |
| TWI805504B (en) | Crystalline form of carboprost tromethamine and preparation process thereof | |
| CN115710209B (en) | Method and intermediate for preparing carboprost and carboprost tromethamine, and carboprost tromethamine prepared therefrom | |
| US20090281301A1 (en) | Manufacturing Process of 2' ,2' - Difluoronucleoside and Intermediate | |
| TWI861431B (en) | Processes and intermediates for the preparations of carboprost and carboprost tromethamine, and carboprost tromethamine prepared therefrom | |
| US7858761B2 (en) | 1-α-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivatives and process for the preparation thereof | |
| WO2019020067A1 (en) | Method for preparing steroid derivative fxr agonist | |
| EP2049558B8 (en) | Naphthalene 2-carboxylate derivative useful for synthesizing gemcitabine and a method for preparing the same | |
| JP2003502338A (en) | Derivatives of 4'-Demicarosyl-8a-aza-8a-homothyrosine | |
| CN120665128A (en) | Compounds, pharmaceutical compositions, kits for capping RNA transcripts, and methods of in vitro transcription |